David Lindsay founded Oncora during his medical training at the University of Pennsylvania, where he received an MD as well as a PhD in engineering for his work developing machine learning technology to assist in the early diagnosis of lung cancer. Dr. Lindsay has deployed machine learning and precision medicine solutions for physicians at leading institutions, impacting the lives of hundreds of thousands of cancer patients worldwide. He is a pioneer in the use of medical imaging as a source of Real World Data to support clinical research. As one of only a handful of healthcare technology CEOs who have actually used EHR software, he holds a unique expertise that helps power Oncora’s product and engineering efforts.
Gary has 25+ years of experience in operations and investments. He joined Safeguard Scientifics in 2006 where he is responsible for identifying, deploying capital in and supporting emerging healthcare companies in diagnostics, medical devices and healthcare IT. Gary is currently a board member of Good Start Genetics, Medivo, meQuilibrium, Propeller Health, Syapse and Trice Medical and is a board observer at Velano Vascular. He recently realized successful exits with partner companies Advanced BioHealing, Alverix, Avid Radiopharmaceuticals, Crescendo Biosciences and NuPathe to strategic acquirers Shire, Becton Dickinson, Eli Lilly, Myriad, and Teva, respectively. Previously, he was Chief Executive Officer at Pluvita Corporation, a company developing personalized medicine solutions and served as Chief Operating Officer at Genovo, and head of research & development at Avigen, both development stage gene therapy companies. Gary began his career in industry with Gilead Sciences as virology group leader. Gary received his MD degree from Washington University, trained in internal medicine at Barnes Hospital in St. Louis, MO, and completed hematology sub-specialty training at Stanford.
Jeff Simon brings over 25 years of experience in medical device hardware and software development, marketing, and commercial operations. Previously, Jeff served as the CEO of Sun Nuclear Corporation where he lead company strategy with responsibility and accountability for all aspects of the business. Jeff is an expert in oncology software sales and marketing as well as a proven corporate leader driving market leading innovation and growth. Jeff serves as a member of Oncora's board of directors and as a senior advisor to Oncora's management team.
Heidi Hendrickson is the co-CEO of Onco, Inc, and investor in and partner of Oncora Medical. Heidi has diverse experience and is a recognized leader in the field of cancer registry software and services. She serves on Oncora's board of directors and provides critical advice to Oncora's CEO regarding sales, marketing, and growth.
Dr. Aaron Kamauu (MD, MS Biomedical Informatics, MPH, University of Utah School of Medicine) is an industry-leading expert in the Real-World Data (RWD) space, specifically focusing on leveraging real-world healthcare data to support a variety of clinical research, informatics, clinical trials, and drug development activities, including pharmacoepidemiology, outcomes research, protocol design, site identification, data-driven patient recruitment, and the use of RWD to support evidence generation & submission to regulatory agencies (e.g., FDA). He has this experience across the spectrum of pharmaceutical/biotech, entrepreneurship, and large CRO businesses. At Oncora, Dr. Kamauu serves as a senior advisor focused on the rigorous design and implementation of RWD/RWE projects throughout the biopharma ecosystem.
Dr. Berlind is a computer scientist and machine learning expert from Georgia Tech and Caltech. He is one of Oncora's original co-founders and now provides advice and support to Oncora's engineering and research teams to ensure that machine learning is appropriately and effectively leveraged for maximum benefit of cancer patients.